Stoke Therapeutics (STOK) Accumulated Expenses (2022 - 2025)
Historic Accumulated Expenses for Stoke Therapeutics (STOK) over the last 4 years, with Q3 2025 value amounting to $30.1 million.
- Stoke Therapeutics' Accumulated Expenses rose 9084.86% to $30.1 million in Q3 2025 from the same period last year, while for Sep 2025 it was $30.1 million, marking a year-over-year increase of 9084.86%. This contributed to the annual value of $18.6 million for FY2024, which is 3439.74% up from last year.
- According to the latest figures from Q3 2025, Stoke Therapeutics' Accumulated Expenses is $30.1 million, which was up 9084.86% from $25.6 million recorded in Q2 2025.
- In the past 5 years, Stoke Therapeutics' Accumulated Expenses registered a high of $30.1 million during Q3 2025, and its lowest value of $11.1 million during Q1 2022.
- In the last 4 years, Stoke Therapeutics' Accumulated Expenses had a median value of $14.0 million in 2022 and averaged $16.6 million.
- As far as peak fluctuations go, Stoke Therapeutics' Accumulated Expenses plummeted by 1227.46% in 2023, and later soared by 9359.59% in 2025.
- Stoke Therapeutics' Accumulated Expenses (Quarter) stood at $15.7 million in 2022, then fell by 12.27% to $13.8 million in 2023, then surged by 34.4% to $18.6 million in 2024, then soared by 62.08% to $30.1 million in 2025.
- Its last three reported values are $30.1 million in Q3 2025, $25.6 million for Q2 2025, and $24.3 million during Q1 2025.